18 Apr 2016 07:00
18 April 2016
Advanced Oncotherapy plc
("Advanced Oncotherapy" or the "Company")
Exercise of Warrants and issue of Shares
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 14,000 new ordinary shares ("New Shares") of 1p in the Company at a price of 6 pence per New Share pursuant to the exercise of 14,000 warrants.
Application has been made for the 14,000 Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or about 21 April 2016. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.
Total voting rights
Following Admission, the Company's enlarged issued share capital will comprise 1,418,342,375 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 1,418,342,375. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Advanced Oncotherapy Plc | www.avoplc.com |
Michael Sinclair, Chief Executive Officer | Tel: +44 20 3617 8728 |
Nicolas Serandour, Chief Operating and Financial Officer |
|
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
|
|
Beaufort Securities (Joint Broker) |
|
Jon Belliss / Elliot Hance | Tel: +44 20 7382 8300 |
|
|
Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.